61 results about "Phosphatidic acid" patented technology

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a synthetic nicotine composition and a preparation method thereof. The nicotine buccal film agent disclosed by the invention is prepared from the following components in parts by weight: 2 to 4 parts of nicotine clathrate compound powder, 0.2 to 0.6 part of phosphatidic acid, 0.1 to 0.3 part of tannic acid, 0.1 to 0.2 part of sodium ascorbate, 0.04 to 0.06 part of tocopherol, 0.01 to 0.02 part of ethylene diamine tetraacetic acid, 2 to 4 parts of povidone and 40 to 80 parts of absolute ethyl alcohol. The synthesized nicotine composition prepared by the invention can effectively relieve the phenomenon that the faster the nicotine is released, the stronger the bitter taste is. Meanwhile, in a high-temperature and high-humidity environment, the stability of nicotine can be effectively maintained, and the oxidation half-life period of nicotine is prolonged.

The present invention relates to a composition comprising, preferably consisting of, (i) a single empty liposome, wherein said single empty liposome is selected from (a) an empty liposome comprising cholesterol, wherein the amount of cholesterol is at least 30% (weight per weight), wherein preferably said empty liposome comprising, further preferably consisting of, cholesterol and sphingomyelin; or (b) an empty liposome consisting of sphingomyelin; or (ii) a mixture of empty liposomes; wherein said mixture of empty liposomes comprises, preferably consists of, at least one empty liposome selected from (a) an empty liposome comprising cholesterol, wherein the amount of cholesterol is at least 30% (weight per weight), wherein preferably said empty liposome comprising, further preferably consisting of, cholesterol and sphingomyelin; (b) an empty liposome consisting of sphingomyelin; and (c) an empty liposome comprising, preferably consisting of, phosphatidylcholine and sphingomyelin; and at least one empty liposome independently of each other selected from an empty liposome comprising, preferably consisting of, lipids or phospholipids selected from cholesterol, sphingomyelins, ceramides, phosphatidylcholines, phosphatidylethanolamines, phosphatidylserines, diacylglycerols, and phosphatidic acids containing one or two or more saturated or unsaturated fatty acids longer than 4 carbon atoms and up to 28 carbon atoms; for use in a method for preventing or reducing biofilm formation or for eradicating or reducing existing biofilm.

The invention belongs to the technical field of medical diagnosis, and provides an HIV (human immunodeficiency virus) combined non-alcoholic fatty liver diagnosis and prediction marker and application. The marker comprises 39 biomarkers in total, wherein the 39 biomarkers comprise two intestinal microorganisms of enterobacter and klebsiella and 37 plasma metabolites of diacylglycerol, lysophosphatidic acid and the like; by integrating microbiome and metabonomics, the multi-dimensional marker is screened and verified, so that the problems of lack of high specificity and sensitivity, difficulty in early disease screening and incapability of effective risk assessment of an HIV (Human Immunodeficiency Virus) combined NAFLD (Non-Amplified Fragment Leukemia) early diagnosis method caused by unknown pathogenesis in the prior art are solved; the marker combination is applicable to preparation of diagnostic kits, construction of disease prediction models and development of targeted therapy drugs, and a theoretical basis is provided for early discovery, risk early warning and advanced intervention of the HIV combined with the non-alcoholic fatty liver disease.

Provided herein are methods and materials for using organisms (e.g., engineered yeast strain-derived) to generate lipid compositions which can modulate cellular aging, extend lifespan, and / or modulate gut homeostasis in a subject. The lipid compositions contain at least twelve of the lipids selected from a phosphatidylethanolamine (PE); a lysophosphatidylethanolamine (LPE); a diacylglycerol (DG); a monoglyceride (MG); an acyl carnitine (AcCa); a phosphatidic acid (PA); a phosphatidylglycerol (PG); a lysophosphatidylcholine (LPC); a triacylglycerol (TG); a cholesterol ester (ChE); a wax ester (WE); a phosphatidylserine (PS); a phosphatidylcholine (PC); a phosphatidylinositol (PI); a ceramide (Cer); and a lysophosphatidylserine (LPS).

An engineered microorganism comprising (i) a heterologous nucleic acid encoding a first lysophosphatidic acid acyltransferase (LPAAT) and (ii) a heterologous nucleic acid encoding a glycerol-3-phosophate acyltransferase (GPAT), a diacylglycerol acyltransferase (DGAT), or a second LPAAT; or a microorganism comprises (i) a heterologous nucleic acid encoding a first lysophosphatidic acid acyltransferase (LPAAT), and (ii) a heterologous nucleic acid encoding a glycerol-3-phosophate acyltransferase (GPAT) or a second LPAAT, optionally further comprising (iii) a heterologous nucleic acid encoding a DGAT; or a microorganism comprising (i) a heterologous nucleic acid encoding a first lysophosphatidic acid acyltransferase (LPAAT), and (ii) a heterologous nucleic acid encoding a second LPAAT, optionally further comprising (iii) a heterologous nucleic acid encoding a DGAT and / or GPAT; or a microorganism comprising a specific LPAAT2, optionally further comprising a heterologous nucleic acid encoding a glycerol-3-phosophate acyltransferase (GPAT), a diacylglycerol acyltransferase (DGAT), or a second LPAAT, and use for the production of triacylglycerol.

The invention relates to the technical field of grease processing, and discloses a method for increasing the sn-2 DHA content in schizochytrium limacinum triglyceride. The method comprises the following steps: adding a metabolic regulator into a fermentation culture solution containing schizochytrium limacinum, carrying out fermentation culture until the total fermentation time is more than 120 hours, and collecting a grease product, the metabolic regulator is selected from at least one of choline chloride, inositol and lysophosphatidic acid. According to the method provided by the invention, the lipid metabolic flux of schizochytrium limacinum can be effectively regulated and controlled, and directional enrichment of DHA to the sn-2 site of triglyceride is remarkably promoted, so that the yield and content of sn-2 DHA are improved.

The invention discloses a TAT peptide modified photolyase liposome as well as a preparation method and application thereof, the method comprises the following steps: S1, mixing and dispersing phosphatidylserine, dipalmitoyl phosphatidyl glycerol, phosphatidic acid and glycerol to obtain a phospholipid-glycerol mixed phase; s2, dissolving photolyase and carboxymethyl chitosan, and adding the dissolved photolyase and carboxymethyl chitosan into the phospholipid-glycerol mixed phase to obtain a photolyase liposome; s3, mixing and dispersing the TAT peptide and the photolysis synthase liposome, so as to obtain the TAT peptide modified photolysis synthase liposome; the TAT peptide modified photolyase liposome has the advantages of mildness, no irritation and low cost, is non-toxic and has biological safety, the storage stability of the TAT peptide modified photolyase liposome can reach 90 days or above, transdermal absorption of active substances can be effectively promoted when the TAT peptide modified photolyase liposome is applied to biological drugs, and the application range of the TAT peptide modified photolyase liposome is widened.

The invention relates to the technical field of gel preparations, in particular to ropivacaine phospholipid gel as well as a preparation method and application thereof. The invention provides ropivacaine phospholipid gel. The ropivacaine phospholipid gel is prepared from ropivacaine, mixed lipid and a hydration solvent, wherein the mixed lipid comprises neutral phospholipid, negative phospholipid and cholesterol, the neutral phospholipid comprises at least one of phosphatidylcholine and phosphatidylcholine derivatives, and the negative phospholipid is phosphatidic acid or phosphatidylglycerol. According to the ropivacaine phospholipid gel, the encapsulation effect and the release characteristic of the ropivacaine phospholipid gel are improved by improving phospholipid raw materials and a preparation process.

The invention discloses an inhibitor for preventing excessive growth of towel gourd strips and application of the inhibitor, and relates to the technical field of planting. The inhibitor comprises the following components: phosphatidic acid, nitrifying bacteria and lignin, wherein the mass ratio of phosphatidic acid to nitrifying bacteria to lignin is (15-20): (16-20): (8-10). The phosphatidic acid and the nitrifying bacteria are introduced, so that the ammonium nitrogen absorption degree of towel gourd roots can be reduced, excessive growth of towel gourds is effectively prevented, the adverse effects of the inhibitor on the growth and quality of the towel gourds are avoided, and the method is low in cost, simple in process and easy to popularize and use.

The invention relates to the technical field of gel preparations, in particular to phospholipid gel as well as a preparation method and application thereof. The invention provides phospholipid gel. The phospholipid gel comprises a raw material medicine, mixed lipid and a hydration solvent, wherein the mixed lipid comprises neutral phospholipid, negative phospholipid and cholesterol, the neutral phospholipid comprises at least one of phosphatidylcholine and phosphatidylcholine derivatives, and the negative phospholipid is phosphatidic acid or phosphatidylglycerol. According to the invention, the encapsulation effect and the release characteristic of the phospholipid gel are improved by improving the phospholipid raw material and the preparation process.

The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are Ami do cyclohexane acid derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of LPA receptors, in particular fibrosis.

The present invention provides agents and methods of modulating the expression, abundance and / or activity of a Lysophosphatidic acid receptor LPAR or Lysophosphatidic acid (LPA) for the treatment and / or prevention of a neurodevelopmental, a neurological or a psychiatric disorder or disease.

No effective ameliorating / therapeutic agent has been provided for dementia, which is centered on Alzheimer-type dementia. The present invention addresses the problem of providing a novel ameliorating / treating agent for dementia by finding an agent capable of ameliorating / treating dementia. According to the present invention, provided is an ameliorating or therapeutic agent for dementia, which contains cyclic phosphatidic acid, carba-cyclic phosphatidic acid, thiacyclic phosphatidic acid, carba-lysophosphatidic acid or a salt thereof.

A persistent encapsulation structure capable of preventing the degradation of bioactive substances, which encapsulation structure comprises a variety of encapsulation structure bodies (10), characterized by that the respective encapsulation structure body (10) has a polysaccharide structure (11) by which a plurality of bioactive substances (12) are encapsulated, wherein the bioactive substance (12) is selected from a group consisting of a bioactive fatty substance (121) and a bioactive non-fatty substance (122); that the polysaccharide structure (11) comprises at least one polysaccharide, wherein the at least one polysaccharide is first thoroughly mixed, then sheared at high pressure or homogenized at high speed and finally atomized dried, such that the polysaccharide structure (11) forms branched polysaccharides and linear polysaccharides which form a multitude of network structures; that the bioactive fatty substance (121) is selected from a group consisting of glycerophospholipids, sphingophospholipids, gangliosides, L-α- / glycerylphosphorylcholines, phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositol, phosphatidylserines, phosphatidic acids, phosphatidylglycerol, ceramides, glucocerebrosides, glycolipids, cholesterols and fatty acid substances; and that the bioactive nonfatty substance (122) is selected from a group of coenzymes, vitamins, carotenes, carotenoids, curcuminoids, curcumin, curcumin extract, polyphenols, saponins, glycosides, terpenoids, ergothioneine, minerals, acid substances, functional polysaccharides, carbohydrates, functional proteins, peptides, amino acids and their derivatives.

The invention belongs to the technical field of molecular diagnosis, and particularly relates to a marker combination for risk assessment when an individual is exposed to electromagnetism and / or noise and application of the marker combination, and markers comprise one or more of 1-stearoyl-2-linoleoyl-sn-glycerin, 1-(9Z, 12Z-octadecadienoyl)-lysophosphatidic acid and N, N-dimethyl phosphatidyl ethanolamine (16: 0 / 16: 0). According to the present invention, the marker can significantly change in the early stage (less than or equal to 7 days) after the individual is exposed by electromagnetism and / or noise, and the abundance level of the marker in the blood sample from the individual is detected so as to rapidly achieve the early, accurate and non-invasive detection of the health risk when the individual is exposed by electromagnetism and / or noise, such that the application prospect is wide.

The invention belongs to the technical field of pharmaceutical chemicals, and particularly relates to a synthesis method of 1, 2-difatty acyl-sn-glycerol-3-phosphatidic acid. According to the synthesis method of the liposome precursor compound 1, 2-double fatty acyl group-sn-glycerol-3-phosphatidic acid, 1, 2-double fatty acyl group-sn-glycerol-3-phosphatidic acid and phosphorus oxychloride are used as raw materials to carry out phosphorylation reaction, then hydrolysis reaction is carried out to obtain the required 1, 2-double fatty acyl group-sn-glycerol-3-phosphatidic acid, and the required 1, 2-double fatty acyl group-sn-glycerol-3-phosphatidic acid is subjected to hydrolysis reaction to obtain the 1, 2-double fatty acyl group-sn-glycerol-3-phosphatidic acid. The two-step phosphorylation-hydrolysis reaction in the whole process can be carried out under the bifunctional catalyst system, the high-efficiency catalytic reaction can be realized without replacing the catalyst, and the product conversion rate is high.

The invention discloses a drug-loaded liposome constructed on the basis of saikoside D, and a preparation method and application of the drug-loaded liposome. The liposome comprises soybean lecithin, saikoside D, phosphatidic acid, an active drug and poloxamer 407. According to the invention, the saikosaponin D with antitumor activity is used for completely replacing cholesterol in the traditional liposome, so that the potential health risk of the cholesterol is avoided, the integration of medicines and auxiliary medicines is realized, and the saikosaponin D and entrapped medicines can generate a synergistic antitumor effect. The modification of the poloxamer 407 endows the liposome with the long circulation characteristic. The preparation method adopts a film dispersion-ultrasonic method, and is simple and convenient to operate. The prepared lipidosome is small in particle size, narrow in distribution and good in stability, the drug loading capacity is about 1.5-7.0%, the tumor cell inhibition effect superior to that of traditional cholesterol lipidosome and free drugs is shown in vitro, and the lipidosome has wide application prospects in the aspect of preparation of anti-tumor drugs.

The invention discloses a method for identifying a sea cucumber producing area based on combination of lipidomics and machine learning, which realizes accurate identification of the sea cucumber producing area by acquiring lipidomics data and screening and identifying markers and combining a machine learning model and interpretability analysis. According to the method, triglyceride, phosphatidic acid and phosphatidyl ethanolamine are obtained through screening as lipid markers, Dalian local sea cucumber and Fujian northern sea cucumber and southern sea cucumber can be accurately distinguished, the method has the advantages of being high in accuracy, high in interpretability and good in universality, and the method can be used for sea cucumber production place identification and supervision sampling inspection; and an effective technical means is provided for aquatic product producing area traceability and identification.

The invention provides a membrane phospholipid composition specific liposome for promoting eggshell mineralization and application thereof. The liposome membrane is prepared from the following components as raw materials: (a) core membrane phospholipid; (b) an acidic phospholipid and (c) a membrane stabilizing component; wherein the core membrane phospholipid comprises PC (Polycarbonate) and PE (Polyethylene); the acidic phospholipid is PS and / or PA; the membrane stabilizing component comprises at least one of methoxy polyethylene glycol modified phosphatidyl ethanolamine (DSPE-PEG), 1, 2-dimyristoyl-rac-glycerol-3-methoxy polyethylene glycol (DMG-PEG), 1, 2-dioleoyl-sn-glycerol-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)] (DOPE-PEG), and cholesterol (Cholesterol). Through specific combination of core membrane phospholipids (PC and PE) and acidic phospholipids (PS and / or PA), an initial mineralization microenvironment in a living body is successfully simulated. In-vitro mineralization test results show that the liposome can effectively promote formation and growth of calcium carbonate crystal nucleuses, has excellent performance on interfaces of eggshell membranes, silicon wafers and the like, and proves universality and effectiveness.

The present disclosure provides compounds and pharmaceutically acceptable salts thereof that inhibit lysophosphatidic acid receptor 1 (LPA1). These compounds are useful, for example, in the treatment of diseases associated with LPA1 activity. The present disclosure also provides compositions containing the compounds as well as methods of using and making the compounds.

A process for degumming a vegetable oil comprising the steps of: a) providing a vegetable oil containing a quantity of phospholipids, b) contacting the oil with one or more phospholipases in presence of water, c) separating the reaction mixture of step b) into a light phase and a heavy phase, and d) producing a degummed vegetable oil, wherein the phospholipase has at least 75 percent sequence identity to SEQ ID NO: 1, wherein more than 75% or 85% or 90% of phosphatidylcholine (PC) and phosphatidylethanolamine (PE) is hydrolyzed, and more than 25% or 35% or 50% of phosphatidic acid (PA) is hydrolyzed and wherein the process is carried out at a temperature of 70°C or above.

The invention discloses recombinant Saccharomyces cerevisiae for producing decaisopentenol as well as a construction method and application of the recombinant Saccharomyces cerevisiae, and belongs to the technical field of microorganisms. The preparation method comprises the following steps: expressing a decaisopentenyl pyrophosphate synthase gene from Rhodobacter sphaeroides in saccharomyces cerevisiae, and carrying out fermentation on the decaisopentenyl pyrophosphate synthase gene to obtain the decaisopentenyl pyrophosphate synthase. Overexpressing the endogenous phosphatidic acid phospholipase gene of the saccharomyces cerevisiae; the recombinant saccharomyces cerevisiae is obtained in a manner of reducing the transcriptional level of a squalene synthesis gene ERG9 and strengthening an MVA endogenous way. According to the method, the production of the decyl isopentenol is realized in the saccharomyces cerevisiae for the first time, the shake flask yield reaches 112mg / L, then the recombinant saccharomyces cerevisiae is fermented to extract the decyl isopentenol, and then the coenzyme Q10 is synthesized by a chemical method, compared with the traditional method for producing the coenzyme Q10 by fermenting the rhodobacter sphaeroides, the method has the advantages of high fermentation stability, simple culture medium and the like, and the method is suitable for industrial production. The industrial application potential is realized.

The invention discloses a preparation method of phosphatidylserine, which comprises the following steps: 1) hydrolyzing crude phospholipid by using broad-spectrum hydrolytic active phospholipase D to generate phosphatidic acid; the invention discloses a method for preparing phosphatidylserine by using crude phospholipid, which comprises the following steps of: 1) preparing phosphatidylserine, 2) inactivating broad-spectrum hydrolysis activity phospholipase D, and 3) adding high transesterification activity phospholipase B and L-serine for esterification.According to the method, the phosphatidylserine can be prepared by directly using the crude phospholipid, the process can be simplified, the production efficiency can be improved, and the production cost can be reduced.

The invention discloses an RVG29 modified ziconotide loaded liposome as well as a preparation method and application thereof. The nano-liposome is prepared from phosphatidylpolyethylene glycol-RVG29, lecithin, cholesterol, phosphatidic acid and ziconotide. The preparation method comprises the following steps: performing repeated washing, resin detection and condensation operation on 2-chlorotrityl chloride resin and the like to prepare RVG29 resin, performing cutting sedimentation treatment and high performance liquid chromatography purification on the RVG29 resin by using phospholipid-polyethylene glycol-active ester and a cutting reagent, and adding lecithin, cholesterol, phosphatidic acid and ziconotide to synthesize and prepare the product liposome. The nano-liposome is a novel nano-liposome for the nose and the brain, gel adhesion and drug delivery are improved, the surface of the liposome targets a nicotinic acetylcholine receptor on the surface of a neuron, accurate drug delivery is achieved, no small-molecule cytotoxic drugs participate in the nano-liposome, the treatment compliance of cancer pain patients is improved, and the nano-liposome is a novel nano-liposome for the nose and the brain. The treatment effect and the life quality are improved.

The application provides a mycoplasma hyopneumoniae culture medium capable of significantly improving the strain titer and an application thereof, and belongs to the field of veterinary biological products. The mycoplasma hyopneumoniae culture medium is obtained by adding L-asparagine, myo-inositol, arachidonic acid, urea, histamine, sodium pyruvate, valproic acid, glyceric acid, lysophosphatidic acid, L-citrulline, L-glutamine and L-leucine into a KM2 culture medium containing Bama pig serum. The culture medium can significantly improve the growth rate and viable bacterial titer of the mycoplasma hyopneumoniae under a low serum concentration, and reduces the production cost.

To provide a compound which inhibits the physiological activity of lysophosphatidic acid (LPA) and is useful as a medicine for treating or preventing diseases for which the inhibition of the physiological activity of LPA is useful.SOLUTION: Provided are compounds having the structure of Formula 1 or a pharmaceutically acceptable salt or prodrug thereof.SELECTED DRAWING: None

The invention provides a method and a kit for diagnosing or identifying whether an individual suffers from liver cancer or not by detecting a metabolic biomarker, and the metabolic biomarker comprises 1-stearoyl-2-arachidonyl-sn-glycerol, NG, S-glycerol, S-glycerol, N-glycerol, N-glycerol, N-glycerol, N-glycerol, N-glycerol, N-glycerol, N-glycerol, N-glycerol and N-glycerol. The compound is selected from one or more of N, N-dimethyl-L-arginine, N, N-dimethyl-L-arginine (ADMA), taurochenodeoxycholic acid, proline-valine (Pro-Val) and 1-oleoyl-L-alpha-lysophosphatidic acid.

The invention provides a construction method and an application of recombinant yarrowia lipolytica for synthesizing furithrolin. The recombinant yarrowia lipolytica is obtained by introducing a combination of a coding gene of tenosyl ether synthase, a coding gene of cytochrome P450 oxidase, a coding gene of cytochrome P450 reductase, a coding gene of acetyltransferase, a coding gene of cytochrome b5 and a coding gene of scaffold protein, and knocking out a coding gene of phosphatidic acid phosphatase at the same time. The efficient synthesis of the fuchsin is realized. The construction method of the yarrowia lipolytica for biosynthesis of the eriolarynx element, provided by the invention, is simple to operate, and the constructed recombinant yarrowia lipolytica can efficiently produce the eriolarynx element and has relatively high production and application values.

The invention relates to the field of biomarker diagnosis, in particular to application of a novel biomarker phosphatidic acid (PA) in preparation of a marker for diagnosing immunotherapy sensitivity of a patient with esophageal squamous carcinoma. Experiments prove that whether a patient responds to immunotherapy (AUC = 0.9450) or not can be effectively diagnosed by detecting the expression quantity of PA in the plasma of the esophageal squamous carcinoma patient, and the key clinical requirements of individualized precise medical treatment and improvement of the overall curative effect are met. Therefore, the method has a wide application prospect.

Extracellular vesicles (PDEVs) for reaching the blood-brain barrier characterized by: be obtained from oranges from organic farming and to contain within the lipid membrane a ratio between the concentration of Phosphatidylethanolamine (PE) and the concentration of Phosphatidic Acid (PA) between 8 and 15.